Abstract
Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m2 over 3 h every 21 days. They received standard premedications and granulocyte colony stimulating factor (G-CSF) support (5 micrograms/kg/day). Median (range) age was 49 (29-81) years and performance status Zubrod was 1 (0-2). One patient had a complete response and seven patients had a partial response (25%, 95% CI 8-38%). The median survival was 7.3 months. Granulocytopenia was brief and non-cumulative. G-CSF was used for a median (range) of 8 (1-15) days per cycle.
In conclusion:
paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated in this dose schedule with G-CSF support.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Agents, Phytogenic / adverse effects
-
Antineoplastic Agents, Phytogenic / therapeutic use*
-
Carcinoma, Squamous Cell / drug therapy*
-
Carcinoma, Squamous Cell / mortality
-
Carcinoma, Squamous Cell / pathology
-
Disease-Free Survival
-
Drug Administration Schedule
-
Female
-
Granulocyte Colony-Stimulating Factor / therapeutic use
-
Humans
-
Infusions, Intravenous
-
Middle Aged
-
Neoplasm Staging
-
Paclitaxel / administration & dosage
-
Paclitaxel / adverse effects
-
Paclitaxel / therapeutic use*
-
Patient Selection
-
Recurrence
-
Survival Rate
-
Uterine Cervical Neoplasms / drug therapy*
-
Uterine Cervical Neoplasms / mortality
-
Uterine Cervical Neoplasms / pathology
Substances
-
Antineoplastic Agents, Phytogenic
-
Granulocyte Colony-Stimulating Factor
-
Paclitaxel